Brief: Glenmark Pharma Q4 Consol Net Profit 46.5 Million Rupees
23/05/2025 15:31
May 23 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA - DIVIDEND OF 2.5 RUPEES PER SHARE GLENMARK PHARMA Q4 CONSOL NET PROFIT 46.5 MILLION RUPEES; IBES EST. 3.16 BILLION RUPEES GLENMARK PHARMA Q4 CONSOL NET SALES 32.2 BILLION RUPEES Q4 EXCEPTIONAL CHARGE OF 3.73 BLN RUPEES Source text: ID:nBSE2HmFmK Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter